Article info

Original research
CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS

Authors

  1. Correspondence to Dr Lucilla Nobbio, DINOGMI, University of Genoa, Genoa 16132, Italy; lnobbio{at}neurologia.unige.it
View Full Text

Citation

Capodivento G, De Michelis C, Carpo M, et al
CSF sphingomyelin: a new biomarker of demyelination in the diagnosis and management of CIDP and GBS

Publication history

  • Received June 30, 2020
  • Revised September 10, 2020
  • Accepted September 25, 2020
  • First published October 22, 2020.
Online issue publication 
February 12, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.